Ilumya, tildrakizumab
Named-patient access overview. Ilumya is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Ilumya
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Ilumya
Ilumya (tildrakizumab) is manufactured by Sun Pharma and indicated for Moderate-to-severe plaque psoriasis in adults. It is an anti-IL-23 (p19) monoclonal antibody (subcutaneous) approved by the US FDA in 2018 and may be accessible to international patients through Named Patient Program or personal-import pathways.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Ilumya
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Ilumya for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Ilumya is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Country coverage
Reserve Meds publishes detailed country deep-dives for our most-requested medications. If you are pursuing Ilumya for a patient in the UAE, Saudi Arabia, India, Egypt, Pakistan, or another market we serve, submit a request and our clinical team will match the destination to the appropriate regulatory pathway and timeline.
Reserved for you. Ilumya is in our coordination scope. Country-specific pricing and timing are confirmed once a coordinator reviews your case.
Start a request for Ilumya
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.
Clinical trials and expanded access
On 17 October 2026 we searched ClinicalTrials.gov, the clinical study registry of the US National Library of Medicine, for studies that list tildrakizumab as an intervention. The search found studies that are recruiting or not yet recruiting. See the current list on ClinicalTrials.gov.
Whether a patient can join a trial or an expanded access program is decided by the study team or the manufacturer, together with the treating doctor. Reserve Meds does not run trials or supply investigational medicines. We can help you and your doctor read a listing and understand the route.
Frequently asked questions
How can I get Ilumya if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Ilumya for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Ilumya through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Ilumya. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Ilumya through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Ilumya to a patient?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Ilumya to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Ilumya cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Ilumya?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.